On July 23 and 24, a federal advisory committee did something unusual. The Food and Drug Administration’s Pharmacy Compounding Advisory Committee recommended that six of the seven peptides it reviewed, among them BPC-157, TB-500, and MOTS-c, be allowed for compounding by licensed pharmacies. It did so over the objection of the FDA’s own scientific reviewers, who had recommended against all seven, citing a lack of clinical evidence.
It is easy to read that as a green light. It is not one, and the gap between what happened and how it will be understood is the story worth following.
What did, and did not, happen
A committee recommendation is not an approval. Nothing has changed in law. The FDA still has to decide whether to accept the recommendation and, if it does, work through its own rulemaking before anything is settled. These peptides remain unapproved drugs. They are not over-the-counter, and the panel’s recommendation covered specific medical uses, not the muscle-recovery and longevity claims that drive most of the demand.
What did happen is a signal of direction. For years, peptides have moved through a gray market faster than regulators could track, sold across the wellness world with little oversight. The July vote is the first real motion toward pulling that market into a licensed, prescribed, pharmacy-compounded system. The door is not open. It is being unlocked.
Where the money will actually go
When a gray market goes legitimate, the revenue does not follow the loudest online seller. It follows the license. And it is worth being honest about who holds the license. The regulated dollars in compounded peptides will flow first to compounding pharmacies, telehealth platforms, and the medical groups that can legally prescribe and dispense. A gym is not, and should not try to become, any of those. The liability and the corporate-practice-of-medicine rules make dispensing the molecule a poor fit for an operator.
The molecule is not the operator’s to own. The relationship is.
That is the more durable position anyway. What a gym or medical-wellness facility can own is the thing the pharmacy and the app cannot: the trusted relationship, the daily touchpoint, the accountability, the front door a member actually walks through. The model that captures this is not a supplement counter. It is a properly structured medical partnership, along the lines of what Life Time built with its MIORA clinics, where a licensed medical practice operates alongside the club and the club owns the member experience.
The operator takeaway
The operators who benefit from this shift will not be the ones racing to sell peptides. They will be the ones who built a credible, credentialed front door before the market fully arrived: a real clinician, real diagnostics, real accountability, and a partnership that keeps the medicine on the right side of the law. Own the relationship, and partner for the medicine. The regulated market will route around whoever tries to shortcut it.